WO1993006857A1 - Preparation and use of human trophoblast membrane expressed protein in an anti-fertility vaccine - Google Patents
Preparation and use of human trophoblast membrane expressed protein in an anti-fertility vaccine Download PDFInfo
- Publication number
- WO1993006857A1 WO1993006857A1 PCT/AU1992/000519 AU9200519W WO9306857A1 WO 1993006857 A1 WO1993006857 A1 WO 1993006857A1 AU 9200519 W AU9200519 W AU 9200519W WO 9306857 A1 WO9306857 A1 WO 9306857A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- human
- vaccine
- expressed protein
- antibody
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 80
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 74
- 210000002993 trophoblast Anatomy 0.000 title claims abstract description 67
- 239000012528 membrane Substances 0.000 title claims abstract description 40
- 229960005486 vaccine Drugs 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 230000003509 anti-fertility effect Effects 0.000 title abstract description 14
- 239000012634 fragment Substances 0.000 claims abstract description 17
- 230000002163 immunogen Effects 0.000 claims abstract description 15
- 241001465754 Metazoa Species 0.000 claims abstract description 12
- 238000004519 manufacturing process Methods 0.000 claims abstract description 11
- 230000035935 pregnancy Effects 0.000 claims abstract description 11
- 230000004936 stimulating effect Effects 0.000 claims abstract description 4
- 102000036639 antigens Human genes 0.000 claims description 39
- 108091007433 antigens Proteins 0.000 claims description 39
- 239000000427 antigen Substances 0.000 claims description 33
- 210000004027 cell Anatomy 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 150000002482 oligosaccharides Polymers 0.000 claims description 13
- 102000003886 Glycoproteins Human genes 0.000 claims description 11
- 108090000288 Glycoproteins Proteins 0.000 claims description 11
- 239000002671 adjuvant Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 108020001507 fusion proteins Proteins 0.000 claims description 7
- 102000037865 fusion proteins Human genes 0.000 claims description 7
- 230000005847 immunogenicity Effects 0.000 claims description 7
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 4
- 125000003729 nucleotide group Chemical group 0.000 claims description 4
- 210000005059 placental tissue Anatomy 0.000 claims description 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 4
- 241000894007 species Species 0.000 claims description 4
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 claims description 3
- 230000005764 inhibitory process Effects 0.000 claims description 3
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 2
- 102000005720 Glutathione transferase Human genes 0.000 claims description 2
- 108010070675 Glutathione transferase Proteins 0.000 claims description 2
- 108010005774 beta-Galactosidase Proteins 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102100026189 Beta-galactosidase Human genes 0.000 claims 1
- 210000002826 placenta Anatomy 0.000 abstract description 15
- 108020004511 Recombinant DNA Proteins 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 4
- 238000001742 protein purification Methods 0.000 abstract description 2
- 235000018102 proteins Nutrition 0.000 description 34
- 210000004379 membrane Anatomy 0.000 description 28
- 210000001519 tissue Anatomy 0.000 description 15
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 230000003169 placental effect Effects 0.000 description 8
- 241001504519 Papio ursinus Species 0.000 description 7
- 239000011324 bead Substances 0.000 description 6
- 230000035558 fertility Effects 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 241000282520 Papio Species 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 238000002649 immunization Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 229960004407 chorionic gonadotrophin Drugs 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 210000003785 decidua Anatomy 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229920001542 oligosaccharide Polymers 0.000 description 3
- 210000005152 placental membrane Anatomy 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- COEXAQSTZUWMRI-STQMWFEESA-N (2s)-1-[2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([C@H](N)C(=O)NCC(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 COEXAQSTZUWMRI-STQMWFEESA-N 0.000 description 2
- UMCMPZBLKLEWAF-BCTGSCMUSA-N 3-[(3-cholamidopropyl)dimethylammonio]propane-1-sulfonate Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCC[N+](C)(C)CCCS([O-])(=O)=O)C)[C@@]2(C)[C@@H](O)C1 UMCMPZBLKLEWAF-BCTGSCMUSA-N 0.000 description 2
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 2
- TZFQICWZWFNIKU-KKUMJFAQSA-N Asn-Leu-Tyr Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 TZFQICWZWFNIKU-KKUMJFAQSA-N 0.000 description 2
- VCJCPARXDBEGNE-GUBZILKMSA-N Asn-Pro-Pro Chemical compound NC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 VCJCPARXDBEGNE-GUBZILKMSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 2
- VMLONWHIORGALA-SRVKXCTJSA-N Ser-Leu-Leu Chemical compound CC(C)C[C@@H](C([O-])=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H]([NH3+])CO VMLONWHIORGALA-SRVKXCTJSA-N 0.000 description 2
- KCGIREHVWRXNDH-GARJFASQSA-N Ser-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CO)N KCGIREHVWRXNDH-GARJFASQSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- DEGUERSKQBRZMZ-FXQIFTODSA-N Val-Ser-Ala Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O DEGUERSKQBRZMZ-FXQIFTODSA-N 0.000 description 2
- LCHZBEUVGAVMKS-RHYQMDGZSA-N Val-Thr-Leu Chemical compound CC(C)C[C@H](NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)[C@@H](C)O)C(O)=O LCHZBEUVGAVMKS-RHYQMDGZSA-N 0.000 description 2
- 108010046516 Wheat Germ Agglutinins Proteins 0.000 description 2
- 108010087924 alanylproline Proteins 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 108010013835 arginine glutamate Proteins 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003433 contraceptive agent Substances 0.000 description 2
- 230000002254 contraceptive effect Effects 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 108010018006 histidylserine Proteins 0.000 description 2
- 239000011539 homogenization buffer Substances 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 102000006495 integrins Human genes 0.000 description 2
- 108010044426 integrins Proteins 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108010064235 lysylglycine Proteins 0.000 description 2
- 230000008774 maternal effect Effects 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000002281 placental hormone Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 108010020532 tyrosyl-proline Proteins 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 1
- ROLXPVQSRCPVGK-XDTLVQLUSA-N Ala-Glu-Tyr Chemical compound N[C@@H](C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O ROLXPVQSRCPVGK-XDTLVQLUSA-N 0.000 description 1
- MQIGTEQXYCRLGK-BQBZGAKWSA-N Ala-Gly-Pro Chemical compound C[C@H](N)C(=O)NCC(=O)N1CCC[C@H]1C(O)=O MQIGTEQXYCRLGK-BQBZGAKWSA-N 0.000 description 1
- SYIFFFHSXBNPMC-UWJYBYFXSA-N Ala-Ser-Tyr Chemical compound C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)O)N SYIFFFHSXBNPMC-UWJYBYFXSA-N 0.000 description 1
- WNHNMKOFKCHKKD-BFHQHQDPSA-N Ala-Thr-Gly Chemical compound [H]N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O WNHNMKOFKCHKKD-BFHQHQDPSA-N 0.000 description 1
- QRIYOHQJRDHFKF-UWJYBYFXSA-N Ala-Tyr-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C)CC1=CC=C(O)C=C1 QRIYOHQJRDHFKF-UWJYBYFXSA-N 0.000 description 1
- REWSWYIDQIELBE-FXQIFTODSA-N Ala-Val-Ser Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(O)=O REWSWYIDQIELBE-FXQIFTODSA-N 0.000 description 1
- GHNDBBVSWOWYII-LPEHRKFASA-N Arg-Asn-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCCN=C(N)N)N)C(=O)O GHNDBBVSWOWYII-LPEHRKFASA-N 0.000 description 1
- IIABBYGHLYWVOS-FXQIFTODSA-N Arg-Asn-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O IIABBYGHLYWVOS-FXQIFTODSA-N 0.000 description 1
- 108010010777 Arg-Gly-Asp-Gly Proteins 0.000 description 1
- AUFHLLPVPSMEOG-YUMQZZPRSA-N Arg-Gly-Glu Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(O)=O AUFHLLPVPSMEOG-YUMQZZPRSA-N 0.000 description 1
- BECXEHHOZNFFFX-IHRRRGAJSA-N Arg-Ser-Tyr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BECXEHHOZNFFFX-IHRRRGAJSA-N 0.000 description 1
- WOZDCBHUGJVJPL-AVGNSLFASA-N Arg-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N WOZDCBHUGJVJPL-AVGNSLFASA-N 0.000 description 1
- NPDLYUOYAGBHFB-WDSKDSINSA-N Asn-Arg Chemical compound NC(=O)C[C@H](N)C(=O)N[C@H](C(O)=O)CCCN=C(N)N NPDLYUOYAGBHFB-WDSKDSINSA-N 0.000 description 1
- DAPLJWATMAXPPZ-CIUDSAMLSA-N Asn-Asn-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(N)=O DAPLJWATMAXPPZ-CIUDSAMLSA-N 0.000 description 1
- GFFRWIJAFFMQGM-NUMRIWBASA-N Asn-Glu-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GFFRWIJAFFMQGM-NUMRIWBASA-N 0.000 description 1
- KLKHFFMNGWULBN-VKHMYHEASA-N Asn-Gly Chemical compound NC(=O)C[C@H](N)C(=O)NCC(O)=O KLKHFFMNGWULBN-VKHMYHEASA-N 0.000 description 1
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 1
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 1
- GLWFAWNYGWBMOC-SRVKXCTJSA-N Asn-Leu-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GLWFAWNYGWBMOC-SRVKXCTJSA-N 0.000 description 1
- JLNFZLNDHONLND-GARJFASQSA-N Asn-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)N)N JLNFZLNDHONLND-GARJFASQSA-N 0.000 description 1
- UOUHBHOBGDCQPQ-IHPCNDPISA-N Asn-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)O)NC(=O)[C@H](CC(=O)N)N UOUHBHOBGDCQPQ-IHPCNDPISA-N 0.000 description 1
- QXOPPIDJKPEKCW-GUBZILKMSA-N Asn-Pro-Arg Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CC(=O)N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O QXOPPIDJKPEKCW-GUBZILKMSA-N 0.000 description 1
- BYLSYQASFJJBCL-DCAQKATOSA-N Asn-Pro-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(C)C)C(O)=O BYLSYQASFJJBCL-DCAQKATOSA-N 0.000 description 1
- CBHVAFXKOYAHOY-NHCYSSNCSA-N Asn-Val-Leu Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O CBHVAFXKOYAHOY-NHCYSSNCSA-N 0.000 description 1
- XOQYDFCQPWAMSA-KKHAAJSZSA-N Asn-Val-Thr Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOQYDFCQPWAMSA-KKHAAJSZSA-N 0.000 description 1
- HPNDBHLITCHRSO-WHFBIAKZSA-N Asp-Ala-Gly Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)NCC(O)=O HPNDBHLITCHRSO-WHFBIAKZSA-N 0.000 description 1
- ILJQISGMGXRZQQ-IHRRRGAJSA-N Asp-Arg-Tyr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O ILJQISGMGXRZQQ-IHRRRGAJSA-N 0.000 description 1
- SVABRQFIHCSNCI-FOHZUACHSA-N Asp-Gly-Thr Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SVABRQFIHCSNCI-FOHZUACHSA-N 0.000 description 1
- IVPNEDNYYYFAGI-GARJFASQSA-N Asp-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CC(=O)O)N IVPNEDNYYYFAGI-GARJFASQSA-N 0.000 description 1
- JXGJJQJHXHXJQF-CIUDSAMLSA-N Asp-Met-Glu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(O)=O JXGJJQJHXHXJQF-CIUDSAMLSA-N 0.000 description 1
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 1
- GIKOVDMXBAFXDF-NHCYSSNCSA-N Asp-Val-Leu Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O GIKOVDMXBAFXDF-NHCYSSNCSA-N 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101800001415 Bri23 peptide Proteins 0.000 description 1
- 102400000107 C-terminal peptide Human genes 0.000 description 1
- 101800000655 C-terminal peptide Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- BUXAPSQPMALTOY-WHFBIAKZSA-N Cys-Glu Chemical compound SC[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O BUXAPSQPMALTOY-WHFBIAKZSA-N 0.000 description 1
- NDNZRWUDUMTITL-FXQIFTODSA-N Cys-Ser-Val Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O NDNZRWUDUMTITL-FXQIFTODSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 239000012594 Earle’s Balanced Salt Solution Substances 0.000 description 1
- LKDIBBOKUAASNP-FXQIFTODSA-N Glu-Ala-Glu Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(O)=O LKDIBBOKUAASNP-FXQIFTODSA-N 0.000 description 1
- RJONUNZIMUXUOI-GUBZILKMSA-N Glu-Asn-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](CCC(=O)O)N RJONUNZIMUXUOI-GUBZILKMSA-N 0.000 description 1
- BFEZQZKEPRKKHV-SRVKXCTJSA-N Glu-Pro-Lys Chemical compound C1C[C@H](N(C1)C(=O)[C@H](CCC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)O BFEZQZKEPRKKHV-SRVKXCTJSA-N 0.000 description 1
- VNCNWQPIQYAMAK-ACZMJKKPSA-N Glu-Ser-Ser Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O VNCNWQPIQYAMAK-ACZMJKKPSA-N 0.000 description 1
- OGCIHJPYKVSMTE-YUMQZZPRSA-N Gly-Arg-Glu Chemical compound [H]NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O OGCIHJPYKVSMTE-YUMQZZPRSA-N 0.000 description 1
- FSPVILZGHUJOHS-QWRGUYRKSA-N Gly-His-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CC1=CNC=N1 FSPVILZGHUJOHS-QWRGUYRKSA-N 0.000 description 1
- UHPAZODVFFYEEL-QWRGUYRKSA-N Gly-Leu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)CN UHPAZODVFFYEEL-QWRGUYRKSA-N 0.000 description 1
- LOEANKRDMMVOGZ-YUMQZZPRSA-N Gly-Lys-Asp Chemical compound NCCCC[C@H](NC(=O)CN)C(=O)N[C@@H](CC(O)=O)C(O)=O LOEANKRDMMVOGZ-YUMQZZPRSA-N 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- ZHHLTWUOWXHVQJ-YUMQZZPRSA-N His-Ser-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)NCC(=O)O)N ZHHLTWUOWXHVQJ-YUMQZZPRSA-N 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- ZFNLIDNJUWNIJL-WDCWCFNPSA-N Leu-Glu-Thr Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O ZFNLIDNJUWNIJL-WDCWCFNPSA-N 0.000 description 1
- XVZCXCTYGHPNEM-UHFFFAOYSA-N Leu-Leu-Pro Natural products CC(C)CC(N)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(O)=O XVZCXCTYGHPNEM-UHFFFAOYSA-N 0.000 description 1
- DRWMRVFCKKXHCH-BZSNNMDCSA-N Leu-Phe-Leu Chemical compound CC(C)C[C@H]([NH3+])C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C([O-])=O)CC1=CC=CC=C1 DRWMRVFCKKXHCH-BZSNNMDCSA-N 0.000 description 1
- CHJKEDSZNSONPS-DCAQKATOSA-N Leu-Pro-Ser Chemical compound [H]N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O CHJKEDSZNSONPS-DCAQKATOSA-N 0.000 description 1
- IRMLZWSRWSGTOP-CIUDSAMLSA-N Leu-Ser-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(O)=O IRMLZWSRWSGTOP-CIUDSAMLSA-N 0.000 description 1
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 1
- RGUXWMDNCPMQFB-YUMQZZPRSA-N Leu-Ser-Gly Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CO)C(=O)NCC(O)=O RGUXWMDNCPMQFB-YUMQZZPRSA-N 0.000 description 1
- ZJZNLRVCZWUONM-JXUBOQSCSA-N Leu-Thr-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O ZJZNLRVCZWUONM-JXUBOQSCSA-N 0.000 description 1
- LINKCQUOMUDLKN-KATARQTJSA-N Leu-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC(C)C)N)O LINKCQUOMUDLKN-KATARQTJSA-N 0.000 description 1
- RIHIGSWBLHSGLV-CQDKDKBSSA-N Leu-Tyr-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C)C(O)=O RIHIGSWBLHSGLV-CQDKDKBSSA-N 0.000 description 1
- OZTZJMUZVAVJGY-BZSNNMDCSA-N Leu-Tyr-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N OZTZJMUZVAVJGY-BZSNNMDCSA-N 0.000 description 1
- LMDVGHQPPPLYAR-IHRRRGAJSA-N Leu-Val-His Chemical compound N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CNC=N1)C(=O)O LMDVGHQPPPLYAR-IHRRRGAJSA-N 0.000 description 1
- SWWCDAGDQHTKIE-RHYQMDGZSA-N Lys-Arg-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SWWCDAGDQHTKIE-RHYQMDGZSA-N 0.000 description 1
- XIZQPFCRXLUNMK-BZSNNMDCSA-N Lys-Leu-Phe Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)NC(=O)[C@H](CCCCN)N XIZQPFCRXLUNMK-BZSNNMDCSA-N 0.000 description 1
- YTJFXEDRUOQGSP-DCAQKATOSA-N Lys-Pro-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(O)=O YTJFXEDRUOQGSP-DCAQKATOSA-N 0.000 description 1
- DYJOORGDQIGZAS-DCAQKATOSA-N Lys-Ser-Met Chemical compound CSCC[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)N DYJOORGDQIGZAS-DCAQKATOSA-N 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- 108010090665 Mannosyl-Glycoprotein Endo-beta-N-Acetylglucosaminidase Proteins 0.000 description 1
- MVBZBRKNZVJEKK-DTWKUNHWSA-N Met-Gly-Pro Chemical compound CSCC[C@@H](C(=O)NCC(=O)N1CCC[C@@H]1C(=O)O)N MVBZBRKNZVJEKK-DTWKUNHWSA-N 0.000 description 1
- YYEIFXZOBZVDPH-DCAQKATOSA-N Met-Lys-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O YYEIFXZOBZVDPH-DCAQKATOSA-N 0.000 description 1
- KZKVVWBOGDKHKE-QTKMDUPCSA-N Met-Thr-His Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC1=CNC=N1 KZKVVWBOGDKHKE-QTKMDUPCSA-N 0.000 description 1
- XZFYRXDAULDNFX-UHFFFAOYSA-N N-L-cysteinyl-L-phenylalanine Natural products SCC(N)C(=O)NC(C(O)=O)CC1=CC=CC=C1 XZFYRXDAULDNFX-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- HNFUGJUZJRYUHN-JSGCOSHPSA-N Phe-Gly-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CC=CC=C1 HNFUGJUZJRYUHN-JSGCOSHPSA-N 0.000 description 1
- YDUGVDGFKNXFPL-IXOXFDKPSA-N Phe-Thr-Cys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)N)O YDUGVDGFKNXFPL-IXOXFDKPSA-N 0.000 description 1
- BPIMVBKDLSBKIJ-FCLVOEFKSA-N Phe-Thr-Phe Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 BPIMVBKDLSBKIJ-FCLVOEFKSA-N 0.000 description 1
- 102000013469 Placental Hormones Human genes 0.000 description 1
- 108010065857 Placental Hormones Proteins 0.000 description 1
- 102000004576 Placental Lactogen Human genes 0.000 description 1
- 108010003044 Placental Lactogen Proteins 0.000 description 1
- 239000000381 Placental Lactogen Substances 0.000 description 1
- 208000032749 Pregnancy Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 1
- FKLSMYYLJHYPHH-UWVGGRQHSA-N Pro-Gly-Leu Chemical compound [H]N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CC(C)C)C(O)=O FKLSMYYLJHYPHH-UWVGGRQHSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- ULWBBFKQBDNGOY-RWMBFGLXSA-N Pro-Lys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CCCCN)C(=O)N2CCC[C@@H]2C(=O)O ULWBBFKQBDNGOY-RWMBFGLXSA-N 0.000 description 1
- HWLKHNDRXWTFTN-GUBZILKMSA-N Pro-Pro-Cys Chemical compound C1C[C@H](NC1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CS)C(=O)O HWLKHNDRXWTFTN-GUBZILKMSA-N 0.000 description 1
- BGWKULMLUIUPKY-BQBZGAKWSA-N Pro-Ser-Gly Chemical compound OC(=O)CNC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1 BGWKULMLUIUPKY-BQBZGAKWSA-N 0.000 description 1
- AJJDPGVVNPUZCR-RHYQMDGZSA-N Pro-Thr-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@@H]1CCCN1)O AJJDPGVVNPUZCR-RHYQMDGZSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- XVAUJOAYHWWNQF-ZLUOBGJFSA-N Ser-Asn-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O XVAUJOAYHWWNQF-ZLUOBGJFSA-N 0.000 description 1
- GHPQVUYZQQGEDA-BIIVOSGPSA-N Ser-Asp-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N)C(=O)O GHPQVUYZQQGEDA-BIIVOSGPSA-N 0.000 description 1
- SQBLRDDJTUJDMV-ACZMJKKPSA-N Ser-Glu-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O SQBLRDDJTUJDMV-ACZMJKKPSA-N 0.000 description 1
- MIJWOJAXARLEHA-WDSKDSINSA-N Ser-Gly-Glu Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(O)=O MIJWOJAXARLEHA-WDSKDSINSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- FBLNYDYPCLFTSP-IXOXFDKPSA-N Ser-Phe-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O FBLNYDYPCLFTSP-IXOXFDKPSA-N 0.000 description 1
- XQJCEKXQUJQNNK-ZLUOBGJFSA-N Ser-Ser-Ser Chemical compound OC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(O)=O XQJCEKXQUJQNNK-ZLUOBGJFSA-N 0.000 description 1
- NERYDXBVARJIQS-JYBASQMISA-N Ser-Trp-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N)O NERYDXBVARJIQS-JYBASQMISA-N 0.000 description 1
- OQSQCUWQOIHECT-YJRXYDGGSA-N Ser-Tyr-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OQSQCUWQOIHECT-YJRXYDGGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 101000895926 Streptomyces plicatus Endo-beta-N-acetylglucosaminidase H Proteins 0.000 description 1
- YZUWGFXVVZQJEI-PMVVWTBXSA-N Thr-Gly-His Chemical compound C[C@H]([C@@H](C(=O)NCC(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O YZUWGFXVVZQJEI-PMVVWTBXSA-N 0.000 description 1
- IJVNLNRVDUTWDD-MEYUZBJRSA-N Thr-Leu-Tyr Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IJVNLNRVDUTWDD-MEYUZBJRSA-N 0.000 description 1
- KKPOGALELPLJTL-MEYUZBJRSA-N Thr-Lys-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 KKPOGALELPLJTL-MEYUZBJRSA-N 0.000 description 1
- NDXSOKGYKCGYKT-VEVYYDQMSA-N Thr-Pro-Asp Chemical compound C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(O)=O)C(O)=O NDXSOKGYKCGYKT-VEVYYDQMSA-N 0.000 description 1
- HUPLKEHTTQBXSC-YJRXYDGGSA-N Thr-Ser-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 HUPLKEHTTQBXSC-YJRXYDGGSA-N 0.000 description 1
- NDZYTIMDOZMECO-SHGPDSBTSA-N Thr-Thr-Ala Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O NDZYTIMDOZMECO-SHGPDSBTSA-N 0.000 description 1
- CSNBWOJOEOPYIJ-UVOCVTCTSA-N Thr-Thr-Lys Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(O)=O CSNBWOJOEOPYIJ-UVOCVTCTSA-N 0.000 description 1
- MYNYCUXMIIWUNW-IEGACIPQSA-N Thr-Trp-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCCCN)C(=O)O)N)O MYNYCUXMIIWUNW-IEGACIPQSA-N 0.000 description 1
- PWONLXBUSVIZPH-RHYQMDGZSA-N Thr-Val-Lys Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)O)N)O PWONLXBUSVIZPH-RHYQMDGZSA-N 0.000 description 1
- BPGDJSUFQKWUBK-KJEVXHAQSA-N Thr-Val-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 BPGDJSUFQKWUBK-KJEVXHAQSA-N 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- FBHHJGOJWXHGDO-TUSQITKMSA-N Trp-Trp-Leu Chemical compound C1=CC=C2C(C[C@H](N)C(=O)N[C@@H](CC=3C4=CC=CC=C4NC=3)C(=O)N[C@@H](CC(C)C)C(O)=O)=CNC2=C1 FBHHJGOJWXHGDO-TUSQITKMSA-N 0.000 description 1
- YMNSKLWJSOANFS-OYDLWJJNSA-N Trp-Trp-Met Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CCSC)C(O)=O YMNSKLWJSOANFS-OYDLWJJNSA-N 0.000 description 1
- IWRMTNJCCMEBEX-AVGNSLFASA-N Tyr-Glu-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)O IWRMTNJCCMEBEX-AVGNSLFASA-N 0.000 description 1
- VTCKHZJKWQENKX-KBPBESRZSA-N Tyr-Lys-Gly Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O VTCKHZJKWQENKX-KBPBESRZSA-N 0.000 description 1
- VNYDHJARLHNEGA-RYUDHWBXSA-N Tyr-Pro Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(O)=O)C1=CC=C(O)C=C1 VNYDHJARLHNEGA-RYUDHWBXSA-N 0.000 description 1
- GAKBTSMAPGLQFA-JNPHEJMOSA-N Tyr-Thr-Tyr Chemical compound C([C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 GAKBTSMAPGLQFA-JNPHEJMOSA-N 0.000 description 1
- AFWXOGHZEKARFH-ACRUOGEOSA-N Tyr-Tyr-His Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(O)=O)C1=CC=C(O)C=C1 AFWXOGHZEKARFH-ACRUOGEOSA-N 0.000 description 1
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 1
- GVJUTBOZZBTBIG-AVGNSLFASA-N Val-Lys-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N GVJUTBOZZBTBIG-AVGNSLFASA-N 0.000 description 1
- QTPQHINADBYBNA-DCAQKATOSA-N Val-Ser-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(O)=O)CCCCN QTPQHINADBYBNA-DCAQKATOSA-N 0.000 description 1
- GBIUHAYJGWVNLN-AEJSXWLSSA-N Val-Ser-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N GBIUHAYJGWVNLN-AEJSXWLSSA-N 0.000 description 1
- GBIUHAYJGWVNLN-UHFFFAOYSA-N Val-Ser-Pro Natural products CC(C)C(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O GBIUHAYJGWVNLN-UHFFFAOYSA-N 0.000 description 1
- GVRKWABULJAONN-VQVTYTSYSA-N Val-Thr Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O GVRKWABULJAONN-VQVTYTSYSA-N 0.000 description 1
- MNSSBIHFEUUXNW-RCWTZXSCSA-N Val-Thr-Arg Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N MNSSBIHFEUUXNW-RCWTZXSCSA-N 0.000 description 1
- SXEHKFHPFVVDIR-UHFFFAOYSA-N [4-(4-hydrazinylphenyl)phenyl]hydrazine Chemical compound C1=CC(NN)=CC=C1C1=CC=C(NN)C=C1 SXEHKFHPFVVDIR-UHFFFAOYSA-N 0.000 description 1
- 239000004015 abortifacient agent Substances 0.000 description 1
- 231100000641 abortifacient agent Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 108010024078 alanyl-glycyl-serine Proteins 0.000 description 1
- 108010047495 alanylglycine Proteins 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 108010009111 arginyl-glycyl-glutamic acid Proteins 0.000 description 1
- 108010060035 arginylproline Proteins 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 102000005936 beta-Galactosidase Human genes 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- OIDPCXKPHYRNKH-UHFFFAOYSA-J chrome alum Chemical compound [K]OS(=O)(=O)O[Cr]1OS(=O)(=O)O1 OIDPCXKPHYRNKH-UHFFFAOYSA-J 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004246 corpus luteum Anatomy 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 229960003983 diphtheria toxoid Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000032692 embryo implantation Effects 0.000 description 1
- 230000002357 endometrial effect Effects 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 108010063718 gamma-glutamylaspartic acid Proteins 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- HPAIKDPJURGQLN-UHFFFAOYSA-N glycyl-L-histidyl-L-phenylalanine Natural products C=1C=CC=CC=1CC(C(O)=O)NC(=O)C(NC(=O)CN)CC1=CN=CN1 HPAIKDPJURGQLN-UHFFFAOYSA-N 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010050475 glycyl-leucyl-tyrosine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- -1 liver and kidney Chemical compound 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 108010003700 lysyl aspartic acid Proteins 0.000 description 1
- 108010017391 lysylvaline Proteins 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 125000000311 mannosyl group Chemical group C1([C@@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 210000000754 myometrium Anatomy 0.000 description 1
- 229950006780 n-acetylglucosamine Drugs 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000186 progesterone Substances 0.000 description 1
- 229960003387 progesterone Drugs 0.000 description 1
- 108010079317 prolyl-tyrosine Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000027272 reproductive process Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- NBFQPSCRGQGZEP-YBKRDZSWSA-N tat 14 Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)CC1=CC=CC=C1 NBFQPSCRGQGZEP-YBKRDZSWSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 108010061238 threonyl-glycine Proteins 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 description 1
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 108010017949 tyrosyl-glycyl-glycine Proteins 0.000 description 1
- 108010071635 tyrosyl-prolyl-arginine Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Definitions
- This invention relates to human trophoblast membrane expressed protein, in particular to the preparation of this protein in substantially pure form and to the use of this protein or an immunologically- active fragment thereof in an anti-fertility vaccine which will interrupt fertility in female animals, including women.
- target antigen for immune attack for interrupting fertility must follow stringent criteria.
- the target antigen must be specific to the reproductive process, that is, it should not share antigenic determinants with normal tissue components in vaccine recipients. Otherwise, the immune response induced by vaccination could elicit damage to normal tissues and/or interfere with normal physiological mechanisms. If shared antigenic determinants are present in the target antigen, unique structures within the macromolecule will have to be identified and synthesised.
- the present invention meets the above criteria as it is concerned with an expressed target glycoprotein antigen of human trophoblast which is apparently restricted to human trophoblast.
- placental antigen targets including placental hormones, and non-hormonal placental antigens.
- Secreted glycoproteins produced by the placenta including the hormones human placental lactogen and human chorionic gonadotrophin (hCG) and the non-hormones ⁇ l-pregnancy- specific glycoprotein from cyanomologous monkeys and placental protein 5 from humans, all showed initial promise, but, with the exception of hCG, have proved to be unreliable as target antigens on testing in sub-human primates' 81 .
- This vaccine may exert its effect by preventing hCG stimulation of the corpus luteum to produce progesterone necessary to maintain a suitable uterine environment for the embryo, or possibly by a direct cytotoxic effect on the hCG- producing cells of the peri-implantation blastocyst.
- a vaccine based on an antigen of the trophoblast surface membrane is that it is expressed only at one anatomical site following fertilisation and is in intimate contact with maternal blood at a very early stage in pregnancy, thus allowing the maternal immune response direct access to the target antigen (15) .
- a second potential advantage of such a vaccine over a hormone-derived formulation is that there is no possible disruption to normal hormone production or function in the recipient. Since the vaccine of the present invention is based on a glycoprotein antigen expressed on the trophoblast membrane surface which is defined by a monoclonal antibody it is, therefore, detected by a single antigenic determinant. This offers a distinct advantage over extracts prepared by conventional purification techniques and defined by polyclonal antisera which contain antibodies reactive to a wide spectrum of proteins.
- this invention provides a vaccine capable of stimulating the production of antibodies which prevent or inhibit pregnancy in a female animal, including a woman, which comprises human trophoblast membrane expressed protein or an immunologically-active fragment thereof, as active immunogen, together with one or more pharmaceutically acceptable carriers or diluents.
- the vaccine further comprises an adjuvant, for example an emulsion of muramyl dipeptide (as adjuvant) and squalene-Arlacel A (as vehicle).
- the vaccine may comprise a second immunogen, such as diphtheria toxin, in order to enhance the immunogenicity of the active immunogen.
- the active immunogen may be the entire full length protein or an immunologically-active fragment thereof.
- Such fragments in particular may be rendered immunogenic either by hapten coupling or by conjugation to a carrier protein of non-human origin.
- the protein or a fragment thereof may be rendered immunogenic by using recombinant DNA technology to synthesise the protein or fragment in the form of a fusion protein, with a heterologous protein or peptide moiety.
- Suitable moieties for use in such a fusion protein include, for example, ⁇ -galactosidase or glutathione-S-transferase (16) .
- the present invention provides a method for the prevention or inhibition of pregnancy in a female animal, including a woman, which comprises administration to said female animal of an antibody- stimulating effective amount of the vaccine as broadly described above.
- human trophoblast membrane expressed protein in substantially pure form.
- substantially pure is meant a form which is at least 70% pure in relation to other proteins, preferably at least 80% pure, and most preferably at least 90% pure.
- this invention provides antibodies, particularly a monoclonal antibody, to human trophoblast membrane expressed protein.
- the invention further extends to a method for the preparation of human trophoblast membrane expressed protein in substantially pure form, which comprises the step of contacting human placental tissue with antibody to the human trophoblast membrane expressed protein, preferably monoclonal antibody thereof, and recovering the desired protein antigen from the antigen/antibody complex.
- the antibody used is adsorbed or covalently bound to a solid support, such as agarose beads, to assist in separating the antigen/antibody complex prior to recovery of the desired protein antigen.
- a solid support such as agarose beads
- the human trophoblast membrane expressed protein of this invention by well-known recombinant DNA technology using conventional expression vectors and host cells to achieve expression of the nucleotide sequence coding for this protein, as set out in Table 1.
- the protein may be produced by this means as the entire full length protein, optionally in the form of a fusion protein as described above. Alternatively, only a part of this nucleotide sequence encoding an immunologically-active fragment may be expressed, and
- SUBSTITUTE SHEET again this fragment may optionally be in the form of a fusion protein.
- Suitable expression vectors, host cells, and recombinant DNA techniques are disclosed by Sambrook et al. (1989)' 17 ', the disclosure of which is incorporated herein by reference.
- the protein antigen of the present invention may be produced either by conventional protein purification means from human placentas, or by using recombinant DNA technology.
- Human trophoblast membrane expressed protein in accordance with the present invention is characterised by the following: (i) it is present on the membrane of villous syncytiotrophoblast of human first trimester and term placentae but is not detected on villous cytotrophoblast cells of human placentae; (ii) on SDS-polyacrylamide gel electrophoresis under both reducing and non-reducing conditions it migrates principally as a species of molecular weight of 63-67kDa; and (iii) it is a glycoprotein which is estimated to contain 3-6 0-linked oligosaccharide chains and 5-10 complex N-linked oligosaccharide chains.
- human trophoblast membrane expressed protein of this invention and of its preparation in substantially pure form and its use in interrupting fertility are described in the following paragraphs, and in the Examples.
- SUBSTITUTE SHEET 1 Description of the Detecting Monoclonal Antibody.
- the human trophoblast membrane expressed protein of this invention was detected by a murine monoclonal antibody, designated FD0338P, which recognises an epitope on that protein.
- This antibody is a mouse monoclonal antibody secreted by a hybridoma cell line which grows indefinitely in tissue culture and can be stored frozen in liquid nitrogen. Further details of this monoclonal antibody, and the production thereof, are given in Example 1.
- the human trophoblast membrane expressed protein of this invention resides on the membrane of villous syncytiotrophoblast of human first trimester and term placentae.
- the epitope was also present on invading, non-villous cytotrophoblast cells of human decidua but at much lower epitope density. It was not detected on villous cytotrophoblast cells of human placentae.
- the epitope of this membrane expressed protein recognised by the FD0338P antibody was not detected on a wide range of other human tissues and cells.
- SUBSTITUTE SHEET ⁇ et.al.' 3 ' bind both syncytiotrophoblast and villous cytotrophoblast.
- the monoclonal antibody described by Loke and Day ( ⁇ ) binds villous cytotrophoblast and endometrial glands' 5 '.
- the pattern of reactivity of FD0338P antibody on human trophoblast and other human tissues was distinct from 45 monoclonal antibodies reacting with human trophoblast components submitted by 12 laboratories to a World Health Organization- sponsored Workshop' 5 '.
- These monoclonal antibodies included two other monoclonal antibodies, and different from FD0338P, contributed from the laboratory of the present inventors. These two antibodies have been described, viz.
- FD046B' 6 ' which recognises a different antigen on syncytiotrophoblast
- FD0161' 7 which detects an antigen on both syncytiotrophoblast and non- villous cytotrophoblast.
- the antigen detected by the monoclonal antibody FD0338P has been prepared from human term placentae.
- the placental tissue is solubilised using a detergent (CHAPS) to release individual membrane proteins.
- CHAPS a detergent
- Agarose (Sepharose) beads with FD0338P antibody covalently attached are then added to the mixture. After suitable incubation the beads are recovered and the antigen, which is bound to the monoclonal antibody, is then dissociated from the antibody using an acid solution.
- the protein eluted from FD0338P gel was shown to contain carbohydrate residues.
- the carbohydrate was removed with trifluoromethanesulphonic acid, resulting in reduction of molecular weight of the protein to 30kDa.
- each oligosaccharide chain contributes between 2-4kDa to the apparent molecular weight on SDS-PAGE gels, it is estimated that the FD0338P glycoprotein has between 8-16 oligosaccharide chains.
- the nature of the oligosaccharide linkage to the polypeptide chain was investigated using endoglycosidases F and H.
- Endoglycosidase F cleaves both complex and high mannose N-linked (i.e.
- First trimester placentas were obtained from elective terminations of apparently healthy pregnancies performed by aspiration at 6-10 weeks' gestation. Clotted blood and any adherent decidua were carefully dissected from the placentas. Syncytiotrophoblast was isolated by gently teasing the placentas through a 250-mesh sieve. The sheets of syncytiotrophoblast, being significantly larger than contaminating cells, readily sediment at unit gravity in Earle's Balanced Salt Solution (Flow Laboratories, Sydney, Australia). After sedimentation for approximately 2 min. the supernatant was decanted and the cells resuspended in fresh solution.
- Balb/c mice were immunised by peritoneal injection with a wheat germ lectin eluate from a solubilised placental membrane extract.
- the wheat germ lectin eluate was prepared using first trimester placenta.
- Placental membrane proteins were solubilised by the addition of an 8mM solution of 3-[(cholamidopropyl)dimethylammonio]1- propanesulphonate (CHAPS) in 20mM Tris-Hcl, pH 8.0 buffer with 0.02% (w/v) sodium azide, 5mM
- CHAPS 3-[(cholamidopropyl)dimethylammonio]1- propanesulphonate
- Ethylenediaminetetra-acetic acid EDTA
- ImM Phenylmethylsulphonylfluoride PMSF
- Germ Agglutinin (WGA) covalently linked to agarose beads (approx. 1 ml of packed beads) was incubated batchwise, with stirring for 17 hours, with the solubilised placental preparation (approx.30 mis). The beads were then recovered by centrifugation at
- the immunogen was given at weekly intervals following a three week delay after the primary injection. After six successive weekly injections the spleen cells from an immunised mouse were fused with mouse myeloma P3x63Ag8.653 cells. The fusion cell mixture was dispensed initially into between two and six 24-well plates and allowed to grow in the presence of RPMI 1640 (Flow Laboratories) medium containing 10% heat- inactivated fetal calf serum (Flow Laboratories), lxl0" 7 M hypoxanthine, 4xl0 "7 M aminopterin, 1.5xl0" 5 M
- IgG secreting clones were identified using an antigen capture ELISA technique. Briefly, ELISA plates were coated with anti-mouse Ig and the culture supernatant from each hybrid colony added. After adequate incubation time and washing, an IgG class specific enzyme conjugated second antibody was added and developed with the appropriate enzyme substrate. IgM secreting clones were discarded and the culture supernatants containing IgG or A were screened for antibody binding activity on frozen sections of first trimester placenta using an immunoperoxidase technique (see below).
- Sections of frozen tissue were cut at -20°C using an American Optical Cryostat. 5 ⁇ m thick sections were air-dried on chrome-alum gelatin- coated slides for 2h. The tissue sections were incubated with cell culture supernatants containing antibodies for eight l-2h at room temperature or overnight at 4°C. Bound antibody was revealed by using biotin-labelled horse antibodies to mouse IgG followed by avidin- biotinylated peroxidase complex (Vector Laboratories, Burlingame, CA;. Diaminobenzidine
- SUBSTITUTE SHEET (DAB) (0.5 mg/ml) with 0.01% hydrogen peroxide in 20mM Imidazole buffer, pH 7.0, was the enzyme substrate. Sections were counterstained with Mayer's Haemalum. Cover slips were then mounted on air dried sections with DePeX.
- Human tissues were obtained as follows: first trimester placenta and decidua were obtained from elective pregnancy terminations, term placentas within lhr or delivery, and endometrium, myometrium, ovary, cervix, stomach, colon and rectum were obtained at surgery. The remainder were obtained within 6h postmortem. Tissues were frozen in liquid nitrogen, then stored at -70"C until required.
- the FD0338P monoclonal antibody was selected on the basis of reactivity with trophoblast cells of human first trimester placenta and the absence of reactivity on other normal (non-malignant) tissues.
- the polyclonal antiserum was raised by immunising sheep with an emulsion composed of
- Adjuvant and 1 volume of 3M potassium chloride solution was prepared by mixing with two syringes interconnected via a narrow tube. Then 1 volume of purified FD0338P protein was blended into the pre-formed emulsion. Sheep were immunised by injecting a total volume of 1ml of the emulsion over 4 sites, subcutaneously. A second and third booster injection were given 21 and 42 days after the primary immunisation. These booster injections were prepared essentially as described above, except that Freund's Incomplete Adjuvant was substituted for the complete adjuvant. Antiserum was collected 21 days after the third injection.
- SUBSTITUTE SHEET the corresponding baboon analogue was achieved by immunising mice with purified FD0338P antigen extracted from human placenta as described above. The mouse spleen cells were then fused with myeloma cells and two distinct cell lines were produced with secreted monoclonal antibodies reactive to the antigen. These monoclonal antibodies also reacted with both human and baboon trophoblast, and have been designated FD078P and FD093P. The presence of the described trophoblast membrane expressed protein in baboon placentae meant that trial testing of immunogenicity and efficacy could be initiated in baboons.
- the antigen used in this initial trial was a denatured preparation which bears little conformational resemblance to the native protein expressed on the surface of the trophoblast membrane.
- Use of the protein in its native conformational state and/or linked to a second, immunogenic protein, for example diphtheria toxoid, before injection is expected to enhance its effectiveness.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
An anti-fertility vaccine capable of stimulating the production of antibodies which prevent or inhibit pregnancy in a female animal, including a woman, comprises human trophoblast membrane expressed protein, or an immunologically-active fragment thereof, as active immunogen. Preparation of human trophoblast membrane expressed protein in substantially pure form from human placentas by conventional protein purification means or by recombinant DNA technology is also disclosed.
Description
PREPARATION AND USE OF HUMAN TROPHOBLAST MEMBRANE EXPRESSED PROTEIN IN AN ANTI-FERTILITY VACCINE
Field of the Invention
This invention relates to human trophoblast membrane expressed protein, in particular to the preparation of this protein in substantially pure form and to the use of this protein or an immunologically- active fragment thereof in an anti-fertility vaccine which will interrupt fertility in female animals, including women.
Introduction.
An immunological approach to interrupting fertility offers several potential advantages viewed in the light of appraisals of the long term safety and acceptability of current contraceptive methods. These advantages include:
(i) the use of a non-pharmacologically active agent; (ii) ease and convenience of administration, suitable for distribution by paramedical personnel; (iϋ) a long-lasting (at least 12 months) but potentially reversible effect; (iv) acceptability of the vaccine principle (of particular importance in developing countries); and (iv) the possible large scale synthesis and manufacture of vaccines at low cost.
SUBSTITUTE SHEET
Selection of a target antigen for immune attack for interrupting fertility must follow stringent criteria. The target antigen must be specific to the reproductive process, that is, it should not share antigenic determinants with normal tissue components in vaccine recipients. Otherwise, the immune response induced by vaccination could elicit damage to normal tissues and/or interfere with normal physiological mechanisms. If shared antigenic determinants are present in the target antigen, unique structures within the macromolecule will have to be identified and synthesised. The present invention meets the above criteria as it is concerned with an expressed target glycoprotein antigen of human trophoblast which is apparently restricted to human trophoblast.
There exist a number of early studies aimed at demonstrating the contraceptive efficacy of some placental antigen targets, including placental hormones, and non-hormonal placental antigens. Secreted glycoproteins produced by the placenta, including the hormones human placental lactogen and human chorionic gonadotrophin (hCG) and the non-hormones βl-pregnancy- specific glycoprotein from cyanomologous monkeys and placental protein 5 from humans, all showed initial promise, but, with the exception of hCG, have proved to be unreliable as target antigens on testing in sub-human primates'81.
Early attempts at demonstrating that placental membrane antigens exerted an anti-fertility effect employed crude placental extracts which acted as an abortifacient, as did administration of antisera to such extracts. These effects, however, were not due to specific immunisation to placental antigens since toxic effects and extra placental tissue damage were seen in the recipients. Several groups have prepared more
SUBSTITUTE SHEET
purified fractions of trophoblast membranes in an attempt to isolate unique protein antigens'9,10,11,12'. The best characterised preparation, TA-1(9) has been tested for anti-fertility effect in baboons and showed encouraging results. TA-1, however, shares antigenic determinants with lymphocytes.
An anti-fertility vaccine formulation based on the C-terminal peptide sequence of the placental hormone, hCG, has been developed(13) and tested for its immunological efficacy and safety(14). This vaccine may exert its effect by preventing hCG stimulation of the corpus luteum to produce progesterone necessary to maintain a suitable uterine environment for the embryo, or possibly by a direct cytotoxic effect on the hCG- producing cells of the peri-implantation blastocyst.
One advantage of a vaccine based on an antigen of the trophoblast surface membrane is that it is expressed only at one anatomical site following fertilisation and is in intimate contact with maternal blood at a very early stage in pregnancy, thus allowing the maternal immune response direct access to the target antigen(15). A second potential advantage of such a vaccine over a hormone-derived formulation is that there is no possible disruption to normal hormone production or function in the recipient. Since the vaccine of the present invention is based on a glycoprotein antigen expressed on the trophoblast membrane surface which is defined by a monoclonal antibody it is, therefore, detected by a single antigenic determinant. This offers a distinct advantage over extracts prepared by conventional purification techniques and defined by polyclonal antisera which contain antibodies reactive to a wide spectrum of proteins.
SUBSTITUTE SHEET
In a first aspect, this invention provides a vaccine capable of stimulating the production of antibodies which prevent or inhibit pregnancy in a female animal, including a woman, which comprises human trophoblast membrane expressed protein or an immunologically-active fragment thereof, as active immunogen, together with one or more pharmaceutically acceptable carriers or diluents. Preferably, the vaccine further comprises an adjuvant, for example an emulsion of muramyl dipeptide (as adjuvant) and squalene-Arlacel A (as vehicle). In addition, the vaccine may comprise a second immunogen, such as diphtheria toxin, in order to enhance the immunogenicity of the active immunogen.
In the anti-fertility vaccine of this invention, the active immunogen may be the entire full length protein or an immunologically-active fragment thereof. Such fragments in particular may be rendered immunogenic either by hapten coupling or by conjugation to a carrier protein of non-human origin. Similarly, the protein or a fragment thereof may be rendered immunogenic by using recombinant DNA technology to synthesise the protein or fragment in the form of a fusion protein, with a heterologous protein or peptide moiety. Suitable moieties for use in such a fusion protein include, for example, β-galactosidase or glutathione-S-transferase(16).
In another aspect, the present invention provides a method for the prevention or inhibition of pregnancy in a female animal, including a woman, which comprises administration to said female animal of an antibody- stimulating effective amount of the vaccine as broadly described above.
SUBSTITUTE SHEET
According to another aspect of the present invention, there is provided human trophoblast membrane expressed protein in substantially pure form. By "substantially pure" is meant a form which is at least 70% pure in relation to other proteins, preferably at least 80% pure, and most preferably at least 90% pure.
In yet another aspect, this invention provides antibodies, particularly a monoclonal antibody, to human trophoblast membrane expressed protein.
The invention further extends to a method for the preparation of human trophoblast membrane expressed protein in substantially pure form, which comprises the step of contacting human placental tissue with antibody to the human trophoblast membrane expressed protein, preferably monoclonal antibody thereof, and recovering the desired protein antigen from the antigen/antibody complex.
Preferably, the antibody used is adsorbed or covalently bound to a solid support, such as agarose beads, to assist in separating the antigen/antibody complex prior to recovery of the desired protein antigen.
Following identification of the corresponding gene in a human placental expression library, it is also possible to prepare the human trophoblast membrane expressed protein of this invention by well-known recombinant DNA technology using conventional expression vectors and host cells to achieve expression of the nucleotide sequence coding for this protein, as set out in Table 1. The protein may be produced by this means as the entire full length protein, optionally in the form of a fusion protein as described above. Alternatively, only a part of this nucleotide sequence encoding an immunologically-active fragment may be expressed, and
SUBSTITUTE SHEET
again this fragment may optionally be in the form of a fusion protein. Suitable expression vectors, host cells, and recombinant DNA techniques are disclosed by Sambrook et al. (1989)'17', the disclosure of which is incorporated herein by reference.
In summary, therefore, the protein antigen of the present invention may be produced either by conventional protein purification means from human placentas, or by using recombinant DNA technology.
Human trophoblast membrane expressed protein in accordance with the present invention is characterised by the following: (i) it is present on the membrane of villous syncytiotrophoblast of human first trimester and term placentae but is not detected on villous cytotrophoblast cells of human placentae; (ii) on SDS-polyacrylamide gel electrophoresis under both reducing and non-reducing conditions it migrates principally as a species of molecular weight of 63-67kDa; and (iii) it is a glycoprotein which is estimated to contain 3-6 0-linked oligosaccharide chains and 5-10 complex N-linked oligosaccharide chains.
The predicted amino acid sequence of this protein, based on the sequence of the corresponding gene identified in a human placental expression library, is set out in Table 1.
Further details of the human trophoblast membrane expressed protein of this invention, and of its preparation in substantially pure form and its use in interrupting fertility are described in the following paragraphs, and in the Examples.
SUBSTITUTE SHEET
1. Description of the Detecting Monoclonal Antibody. The human trophoblast membrane expressed protein of this invention was detected by a murine monoclonal antibody, designated FD0338P, which recognises an epitope on that protein. This antibody is a mouse monoclonal antibody secreted by a hybridoma cell line which grows indefinitely in tissue culture and can be stored frozen in liquid nitrogen. Further details of this monoclonal antibody, and the production thereof, are given in Example 1.
Using this antibody (immunoglobulin heavy chain class Gl, light chain Kappa), it has been established that the human trophoblast membrane expressed protein of this invention resides on the membrane of villous syncytiotrophoblast of human first trimester and term placentae. The epitope was also present on invading, non-villous cytotrophoblast cells of human decidua but at much lower epitope density. It was not detected on villous cytotrophoblast cells of human placentae. The epitope of this membrane expressed protein recognised by the FD0338P antibody was not detected on a wide range of other human tissues and cells.
The cell and tissue distribution of this trophoblast membrane expressed protein antigen is distinct from other trophoblast antigens previously described. Thus the monoclonal antibodies described by Johnson et.al.'1' which react with syncytiotrophoblast also recognise decidual glands (H315) or lymphocytes (H316). The antibody ND0G1(2) binds syncytiotrophoblast and cytotrophoblast and recognises a carbohydrate epitope. Trop.l and Trop.2, described by Lipinski
SUBSTITUTE SHEET
δ et.al.'3' bind both syncytiotrophoblast and villous cytotrophoblast. The monoclonal antibody described by Loke and Day(<) binds villous cytotrophoblast and endometrial glands'5'. The pattern of reactivity of FD0338P antibody on human trophoblast and other human tissues was distinct from 45 monoclonal antibodies reacting with human trophoblast components submitted by 12 laboratories to a World Health Organisation- sponsored Workshop'5'. These monoclonal antibodies included two other monoclonal antibodies, and different from FD0338P, contributed from the laboratory of the present inventors. These two antibodies have been described, viz. FD046B'6' which recognises a different antigen on syncytiotrophoblast, and FD0161'7' which detects an antigen on both syncytiotrophoblast and non- villous cytotrophoblast.
2. Production of the Trophoblast Membrane Expressed Protein.
The antigen detected by the monoclonal antibody FD0338P has been prepared from human term placentae. The placental tissue is solubilised using a detergent (CHAPS) to release individual membrane proteins. Agarose (Sepharose) beads with FD0338P antibody covalently attached are then added to the mixture. After suitable incubation the beads are recovered and the antigen, which is bound to the monoclonal antibody, is then dissociated from the antibody using an acid solution.
Molecular Weight of the Trophoblast Membrane Expressed Protein.
SUBSTITUTESHEET
On SDS-polyacrylamide gel electrophoresis, the antigen prepared by affinity chromatography (as described above) migrates as a series of molecular weight entities ranging from 30kDa through to the largest, 67kDa. The same bands are seen under both reducing and non-reducing conditions, indicating that the protein does not possess either inter- or intrachain disulphide bonds. The two largest and most abundant species namely, the 63 and 67kDa bands have been isolated to apparent homogeneity by electro-elution from the SDS-polyacrylamide gel.
4. Glycosylation of the Trophoblast Membrane Expressed Protein.
The protein eluted from FD0338P gel was shown to contain carbohydrate residues. The carbohydrate was removed with trifluoromethanesulphonic acid, resulting in reduction of molecular weight of the protein to 30kDa. Assuming that each oligosaccharide chain contributes between 2-4kDa to the apparent molecular weight on SDS-PAGE gels, it is estimated that the FD0338P glycoprotein has between 8-16 oligosaccharide chains. The nature of the oligosaccharide linkage to the polypeptide chain was investigated using endoglycosidases F and H. Endoglycosidase F cleaves both complex and high mannose N-linked (i.e. to asparagine residues), but not O-linked (i.e. serine/threonine residues) oligosaccharides. Cleavage with this enzyme reduced the molecular weights of the two major bands from 63 and 67kDa to 43 and 48kDa respectively. Endoglycosidase H cleaves only high mannose-type N-linked oligosaccharides. No reduction in molecular weight was seen after treatment with this enzyme indicating an absence
SUBSTITUTESHEET
of high mannose chains. Thus the FD0338P glycoprotein appears to have between 3-6 O-linked oligosaccharide chains and 5-10 complex N-linked oligosaccharide chains.
5. Isolation of FD0338P Gene
Using polyclonal antisera raised against the affinity purified FD0338P glycoprotein in sheep, a commercial human placental 32 week λgtll cDNA expression library was probed for the expression of the corresponding antigen using conventional procedures as detailed in Sambrook et. al. (1989)'17'. Isolation of the correct clone was confirmed on Western blots using the expressed fusion protein (i.e. β-galactosidase-FD0338P antigen). The Western blot was probed with monoclonal antibody designated FD078P, raised against affinity-purified FD0338P glycoprotein from human term placentas (see Example 2). The clone was sequenced and the DNA sequence is shown on Table 1, together with the predicted amino acid sequence for the FD0338P protein. Using the sequenced cDNA, and a computer aided data base search (Genbank & EMBL) it was found that this gene had previously been cloned and sequenced by
Rooney et. al . (1988)'18'. Sequence analysis of the cDNA showed that the gene encoded a protein related to the Schwangerschaft protein-1 (SP-1) group of protein, which in turn is a subset of the carcinoembyonic antigens (CEA) and a further subset of the super family of immunoglobulins. An interesting feature of the amino acid sequence of the protein is the presence of an "RGD" (Arg-Gly- Asp) motif. This motif is an integrin receptor consensus sequence. Integrin is a cell receptor protein thought to be intimately involved with binding to extracellular matrices (19).
SUBSTITUTE SHEET
Consequently, one possible function of the protein of the invention is the facilitation of blastocyst implantation.
The following Examples describe in detail the production of a monoclonal antibody to the human trophoblast membrane expressed protein of this invention, and the immunogenicity and anti-fertility testing of this protein.
EXAMPLE 1
Production of Monoclonal Antibody a. Syncytiotrophoblast preparation.
First trimester placentas were obtained from elective terminations of apparently healthy pregnancies performed by aspiration at 6-10 weeks' gestation. Clotted blood and any adherent decidua were carefully dissected from the placentas. Syncytiotrophoblast was isolated by gently teasing the placentas through a 250-mesh sieve. The sheets of syncytiotrophoblast, being significantly larger than contaminating cells, readily sediment at unit gravity in Earle's Balanced Salt Solution (Flow Laboratories, Sydney, Australia). After sedimentation for approximately 2 min. the supernatant was decanted and the cells resuspended in fresh solution. This washing procedure was performed three times, then the cells were either used for immunisation in mice or placed into culture. The success of trophoblast isolation was confirmed by the synthesis of human chorionic gonadotrophin in culture after three days incubation. Human chorionic gonadotrophin concentration was measured with a solid phase two- site immunoradiometric assay (Hybritech,
California, USA).
SUBSTITUTE SHEET
Generation of monoclonal antibodies.
Balb/c mice were immunised by peritoneal injection with a wheat germ lectin eluate from a solubilised placental membrane extract. The wheat germ lectin eluate was prepared using first trimester placenta. Placental membrane proteins were solubilised by the addition of an 8mM solution of 3-[(cholamidopropyl)dimethylammonio]1- propanesulphonate (CHAPS) in 20mM Tris-Hcl, pH 8.0 buffer with 0.02% (w/v) sodium azide, 5mM
Ethylenediaminetetra-acetic acid (EDTA) and ImM Phenylmethylsulphonylfluoride (PMSF) in the ratio of 1:10 (w/v). After stirring for 17 hours at 4°C the insoluble material was removed by centrifugation at 2,000g for 15 minutes. Wheat
Germ Agglutinin (WGA) covalently linked to agarose beads (approx. 1 ml of packed beads) was incubated batchwise, with stirring for 17 hours, with the solubilised placental preparation (approx.30 mis). The beads were then recovered by centrifugation at
200 g for five minutes and transferred to a column for washing with fresh homogenisation buffer. The immobilised proteins were eluted from the gel with three volumes of 200 mM N-acetylglucosamine in homogenisation buffer.
The immunogen was given at weekly intervals following a three week delay after the primary injection. After six successive weekly injections the spleen cells from an immunised mouse were fused with mouse myeloma P3x63Ag8.653 cells. The fusion cell mixture was dispensed initially into between two and six 24-well plates and allowed to grow in the presence of RPMI 1640 (Flow Laboratories) medium containing 10% heat- inactivated fetal calf serum (Flow Laboratories), lxl0"7M hypoxanthine, 4xl0"7M aminopterin, 1.5xl0"5M
SUBSTITUTESHEET
thymidine, 100 units/ml penicillin and 100 μg/ml streptomycin at 37°C in a humid atmosphere of 5% C02 in air for about 10 days. A few cells from each hybrid colony were then picked out and transferred to individual wells of other 24-well plates. To both minimise the probability of identifying carbohydrate epitopes and facilitate the possible use in an immuno-affinity gel, IgG secreting clones were identified using an antigen capture ELISA technique. Briefly, ELISA plates were coated with anti-mouse Ig and the culture supernatant from each hybrid colony added. After adequate incubation time and washing, an IgG class specific enzyme conjugated second antibody was added and developed with the appropriate enzyme substrate. IgM secreting clones were discarded and the culture supernatants containing IgG or A were screened for antibody binding activity on frozen sections of first trimester placenta using an immunoperoxidase technique (see below).
Cultures of interest were then cloned twice by the limiting dilution method and further expanded in culture.
c. Tissue specificity of monoclonal antibodies by immunoperoxidase staining of frozen tissue sections.
Sections of frozen tissue were cut at -20°C using an American Optical Cryostat. 5μm thick sections were air-dried on chrome-alum gelatin- coated slides for 2h. The tissue sections were incubated with cell culture supernatants containing antibodies for eight l-2h at room temperature or overnight at 4°C. Bound antibody was revealed by using biotin-labelled horse antibodies to mouse IgG followed by avidin- biotinylated peroxidase complex (Vector Laboratories, Burlingame, CA;. Diaminobenzidine
SUBSTITUTE SHEET
(DAB) (0.5 mg/ml) with 0.01% hydrogen peroxide in 20mM Imidazole buffer, pH 7.0, was the enzyme substrate. Sections were counterstained with Mayer's Haemalum. Cover slips were then mounted on air dried sections with DePeX.
For tissues containing substantial amounts of endogenous biotin such as liver and kidney, an indirect immunoperoxidase technique was used. An appropriate dilution of peroxidase-labelled goat anti-mouse IgG reduced the high background staining found with the avidin-peroxidase complex technique.
Human tissues were obtained as follows: first trimester placenta and decidua were obtained from elective pregnancy terminations, term placentas within lhr or delivery, and endometrium, myometrium, ovary, cervix, stomach, colon and rectum were obtained at surgery. The remainder were obtained within 6h postmortem. Tissues were frozen in liquid nitrogen, then stored at -70"C until required.
A monoclonal antibody (FD0114G) produced in the laboratory, which reacts with Type IV collagen, acted as a positive control on all tissues.
d. Selection of monoclonal antibody to human trophoblast membrane expressed protein.
The FD0338P monoclonal antibody was selected on the basis of reactivity with trophoblast cells of human first trimester placenta and the absence of reactivity on other normal (non-malignant) tissues.
SUBSTITUTE SHEET
EXAMPLE 2 Immunogenicity and Anti-fertility Testing a. Identification of the FD0338P protein on baboon trophoblast. The murine monoclonal antibody, FD0338P, described in Example 1, which detects the human trophoblast membrane expressed protein did not react with baboon trophoblast. However, a sheep polyclonal antiserum raised to purified FD0338P antigen extracted from human placenta, did react with baboon trophoblast. The baboon analogue had a similar molecular weight to the human protein.
The polyclonal antiserum was raised by immunising sheep with an emulsion composed of
Freund's adjuvant and I6μg of purified FD0338P antigen (purified as described above - Production of the Trophoblast Membrane Expressed Protein). Briefly, for the primary immunisation an emulsion formed between 2 volumes of Freund's Complete
Adjuvant and 1 volume of 3M potassium chloride solution, was prepared by mixing with two syringes interconnected via a narrow tube. Then 1 volume of purified FD0338P protein was blended into the pre-formed emulsion. Sheep were immunised by injecting a total volume of 1ml of the emulsion over 4 sites, subcutaneously. A second and third booster injection were given 21 and 42 days after the primary immunisation. These booster injections were prepared essentially as described above, except that Freund's Incomplete Adjuvant was substituted for the complete adjuvant. Antiserum was collected 21 days after the third injection.
Confirmation of the similarity between the FD0338P protein isolated from human placenta and
SUBSTITUTE SHEET
the corresponding baboon analogue was achieved by immunising mice with purified FD0338P antigen extracted from human placenta as described above. The mouse spleen cells were then fused with myeloma cells and two distinct cell lines were produced with secreted monoclonal antibodies reactive to the antigen. These monoclonal antibodies also reacted with both human and baboon trophoblast, and have been designated FD078P and FD093P. The presence of the described trophoblast membrane expressed protein in baboon placentae meant that trial testing of immunogenicity and efficacy could be initiated in baboons.
Immunogenicity and anti-fertility testing of FD0338P protein in baboons.
In an initial study to demonstrate utility, three baboons were immunised intramuscularly with 16μg of human FD0338P protein. The SDS-denatured protein was mixed with an emulsion of muramyl dipeptide and squalene-Arlacel A. This emulsion has been approved for, and used in, a Phase 1 Trial of the hCG-based anti-fertility vaccine in humans. Injections were given on Day 0, 21, 42 and 140 (2 animals only). Baboons were mated after the second injection and in subsequent cycles until pregnancy resulted.
All three animals responded by raising antibodies (tested by ELISA assay to the immunising antigen), the titres increased after each injection, indicating that the antigen is immunogenic. One animal became pregnant in the first mating cycle, the second in the second cycle while the third was protected until the fourth cycle. The overall fertility rate was 33%, compared to the average colony fertility rate of 70%. This preliminary and limited trial indicates
SUBSTITUTE SHEET
the potential use of the FD0338P protein in an anti-fertility vaccine formulation.
It will be appreciated that several approaches can be taken to improve both the immunogenicity and thus the anti-fertility effect of the FD0338P protein as described above. For example, the antigen used in this initial trial was a denatured preparation which bears little conformational resemblance to the native protein expressed on the surface of the trophoblast membrane. Use of the protein in its native conformational state and/or linked to a second, immunogenic protein, for example diphtheria toxoid, before injection is expected to enhance its effectiveness.
SUBSTITUTE SHEET
TABLE 1
DNA SEQUENCE AND PREDICTED AMINO ACID SEQUENCE
GGG CGG GAC AAC TGG TCT GAG TAC TAT GGC TGA TTT TCG CTG TCT GGC 48
ATT GAG AAG CCA CAC GCC CCT TTT GCT TAG GAG GCC TCT CTG CTG GAG 96
GAT GAC GAT GGC ATG GTT TAT CTA AGG CCA CTG ACA AGT CAT CAA TAT 14
AGG ACA GCA CAG CTG AGA GCC ATG CTC AGG AAG TTT CTG GAT CCT AGG 192
Met Gly Pro 3 CTC AGC TCC ACA GAG GAG AAC ACG CAG GCA GCA GAG ACC ATG GGG CCC 2 0 Leu Ser Ala Pro Pro Cys Thr Gin Arg lie Thr Trp Lys Gly Leu Leu 19 CTC TCA GCC CCT CCC TGC ACA CAG CGC ATC ACC TGG AAG GGG CTC CTG 288 Leu Thr Ala Ser Leu Leu Asn Phe Trp Asn Pro Pro Thr Thr Ala Gin 35 CTC ACA GCA TCA CTT TTA AAC TTC TGG AAC CCG CCT ACC ACT GCC CAA 336 Val Thr He Glu Ala Glu Pro Thr Lys Val Ser Lys Gly Lys Asp Val 51 GTC ACG ATT GAA GCC GAG CCA ACC AAA GTT TCC AAG GGG AAG GAC GTT 384 Leu Leu Leu Val His Asn Leu Pro Gin Asn Leu Ala Gly Tyr lie Trp 67 CTT CTA CTT GTC CAC AAT TTG CCC CAG AAT CTT GCT GGC TAC ATC TGG 432 Tyr Lys Gly Gin Met Lys Asp Leu Tyr His Tyr He Thr Ser Tyr Val 83 TAC AAA GGG CAA ATG AAG GAC CTC TAC CAT TAC ATT ACA TCA TAC GTA 80 Val Asp Gly Gin He He He Tyr Gly Pro Ala Tyr Ser Gly Arg Glu 99 GTA GAT GGT CAA ATA ATT ATA TAT GGG CCT GCA TAC AGT GGA CGA GAA 528 Thr Val Tyr Ser Asn Ala Ser Leu Leu He Gin Asn Val Thr Arg Glu 115 ACA GTA TAT TCC AAT GCA TCC CTG CTG ATC CAG AAT GTC ACC CGG GAG 576 Asp Ala Gly Ser Tyr Thr Leu His He Val Lys Arg Gly Asp Gly Thr 131 GAC GCA GGA TCC TAC ACC TTA CAC ATC GTA AAG CGA GGT GAT GGG ACT 624 Arg Gly Glu Thr Gly His Phe Thr Phe Thr Leu Tyr Leu Glu Thr Pro 147 AGA GGA GAA ACT GGA CAT TTC ACC TTC ACC TTA TAC CTG GAG ACT CCC 672 Lys Pro Ser He Ser Ser Ser Asn Leu Tyr Pro Arg Glu Asp Met Glu 163 AAG CCC TCC ATC TCC AGC AGC AAC TTA TAC CCC AGG GAG GAC ATG GAG 720 Ala Val Ser Leu Thr Cys Asp Pro Glu Thr Pro Asp Ala Ser Tyr Leu 179 GCT GTG AGC TTA ACC TGT GAT CCT GAG ACT CCG GAC GCA AGC TAC CTG 768 Trp Trp Met Asn Gly Gin Ser Leu Pro Met Thr His Ser Lc-u Gin Leu 195 TGG TGG ATG AAT GGT CAG AGC CTC CCT ATG ACT CAC AGC TIG CAG TTG 816
SUBSTITUTESHEET
TABLE 1 (CONT. )
196 Ser Lys Asn Lys Arg Thr Leu Phe Leu Phe Gly Val Thr Lys Tyr Thr 211
817 TCC AAA AAC AAA AGG ACC CTC TTT CTA TTT GGT GTC ACA AAG TAC ACT 864
212 Ala Gly Pro Tyr Glu Cys Glu He Arg Asn Pro Val Ser Ala Ser Arg 227
865 GCA GGA CCC TAT GAA TGT GAA ATA CGG AAC CCA GTG AGT GCC AGC CGC 912
228 Ser Asp Pro Val Thr Leu Asn Leu Leu Pro Lys Leu Pro Lys Pro Tyr 243
913 AGT GAC CCA GTC ACC CTG AAT CTC CTC CCG AAG CTG CCC AAG CCC TAC 960
244 He Thr He Asn Asn Leu Asn Pro Arg Glu Asn Lys Asp Val Leu Ala 259
961 ATC ACC ATC AAC AAC TTA AAC CCC AGG GAG AAT AAG GAT GTC TTA GCC 1008
260 Phe Thr Cys Glu Pro Lys Ser Glu Asn Tyr Thr Tyr He Trp Trp Leu 275
1009 TTC ACC TGT GAA CCT AAG AGT GAG AAC TAC ACC TAC ATT TGG TGG CTA 1056
276 Asn Gly Gin Ser Leu Pro Val Ser Pro Arg Val Lys Arg Pro He Glu 291
1057 AAT GGT CAG AGC CTC CCG GTC AGT CCC AGG GTA AAG CGA CCC ATT GAA 1104
292 Asn Arg He Leu He Leu Pro Ser Val Thr Arg Asn Glu Thr Gly Pro 307
1105 AAC AGG ATC CTC ATT CTA CCC AGT GTC ACG AGA AAT GAA ACA GGA CCC 1152
308 Tyr Gin Cys Glu He Gin Asp Arg Tyr Gly Gly He Arg Ser Tyr Pro 323
1153 TAT CAA TGT GAA ATA CAG GAC CGA TAT GGT GGC ATC CGC AGT TAC CCA 1200
324 Val Thr Leu Asn Val Leu Tyr Gly Pro Asp Leu Pro Arg He Tyr Pro 339
1201 GTC ACC CTG AAT GTC CTC TAT GGT CCA GAC CTC CCC AGA ATT TAC CCT 12 8
340 Ser Phe Thr Tyr Tyr His Ser Gly Glu Asn Leu Tyr Leu Ser Cys Phe 355
1249 TCA TTC ACC TAT TAC CAT TCA GGA GAA AAC CTC TAC TTG TCC TGC TTC 1296
356 Ala Asp Ser Asn Pro Pro Ala Glu Tyr Ser Trp Thr He Asn Gly Lys 371
1297 GCG GAC TCT AAC CCA CCA GCA GAA TAT TCT TGG ACA ATT AAT GGG AAG 1344
372 Phe Gin Leu Ser Gly Gin Lys Leu Phe He Pro Gin He Thr Thr Lys 387
13 5 TTT CAG CTA TCA GGA CAA AAG CTC TTT ATC CCC CAG ATT ACT ACA AAG 1392
388 His Ser Gly Leu Tyr Ala Cys Ser Val Arg Asn Ser Ala Thr Gly Met 403
1393 CAT AGC GGG CTC TAT GCT TGC TCT GTT CGT AAC TCA GCC ACT GGC ATG 1440
404 Glu Ser Ser Lys Ser Met Thr Val Lys Val Ser Ala Pro Ser Gly Thr 419
1441 GAA AGC TCC AAA TCC ATG ACA GTC AAA GTC TCT GCT CCT TCA GGA ACA 1488
420 Gly His Leu Pro Gly Leu Asn Pro Leu ***
1489 GGA CAT CTT CCT GGC CTT AAT CCA TTA TAG CAG CCG TGA TGT CAT TTC 1536
1537 TGT ATT TCA GGA AGA CTG GCA GAC AGT TGC TTT CAT TCT TCC TCA AAG 1584
1585 TAT TTA CCA TCA GCT ACA GTC CAA AAT TGC TTT TTG TTC AAG GAG ATT 1632
1633 TAT GAA AAG ACT CTG ACA AGG ACT CTT GAA TAC AAG TTC CTG ATA ACT 1680
SUBSTITUTE SHEET
TABLE 1 ( CONT . )
1681 TCA AGA TCA TAC ATG GAC TAA GAA CTT TCA AAA TTT TAA TGA ACA GGC 1728
1729 TGA TAC TTC ATG AAA TTC AAG ACA AAG AAA AAA ACC CAA TTT TAT TGG 1776
1777 ACT AAA TAG TCA AAA CAA TGT TTT CAT AAT TTT CTA TTT GAA AAT GTG 1824
1825 CTG ATT CTT TGA ATG TTT TAT TCT CCA GAT TTA TGC ACT TTT TTT CTT 1872
1873 CAG CAA TTG GTA AAG TAT ACT TTT GTA AAC AAA AAT TGA AAC ATT TGC 1920
1921 TTT TGC TCC CTA AGT GCC CCA GAA TTG GGA AAC TAT TCA GGA GTA TTC 1968
1969 ATA TGT TTA TGG TAA TAA AGT TAT CTG CAC AAA CCC
SUBSTITUTE SHEET
REFERENCES:
1. Johnson, P.M. et.al. (1981). Am. J. Reprod. Immunol. 3. :246.
2. Sunderland, CA. et.al. (1981). Immunology 43 :541.
3. Lipinski, M. et.al. (1981). Proc. Natl. Acad. Sci. (USA). 78 : 5147.
4. Loke, Y.W. and Day, S. (1984). Am. J. Reprod. Immunol. 5. : 106.
5. Anderson, D.J. et.al. (1987). J.Reprod. Immunol. 10 :231.
6. Mueller, U.W. et.al. (1986. Immunology 59 :135.
7. Mueller, U.W. et.al. (1987). Histochem. J.. 19 : 288.
8. Jones, W.R. (1982). "Immunological Fertility Regulation", Blackwell, Oxford.
9. Faulk, W.P. et.al. (1987). Immunological Influence on Human Fertility (ed. B.Boettcher). p.153, Academic Press, Sydney.
10. Faulk, W.P. et.al. (1978). Proc. Natl. Acad. Sci. (USA). 75 : 1947.
11. Ogbimi, A.O. et.al. (1979). J. Reprod. Immunol. 1 : 127.
12. Whyte, A. and Loke, Y.W. (1979). Clin. Exp. Immunol. 37 : 359.
13. Stevens, V.C. (1986). Immunology Today 7 : 369.
14. Jones, W.R. et.al. (1988). Lancet 1 : 1295.
15. Ada, G.L. et.al. (1985). Nature 317 : 288.1
16. Smith and Johnson (1988). Gene. 67 : 31.
17. Sambrook et.al. (1989). "Molecular Cloning : A Laboratory Manual." Cold Spring Harbor, New York.
18. Rooney et.al. (1988). Gene. 71 : 439.
19. Ruoslahti and Pierschbacher (1987). Science. 238 : 491.
SUBSTITUTESHEET
Claims
1. A vaccine capable of stimulating the production of antibodies which prevent or inhibit pregnancy in female animals, including women, which comprises human trophoblast membrane expressed protein, or an immunologically-active fragment thereof, as active immunogen, together with one or more pharmaceutically acceptable carriers or diluents.
2. A vaccine according to claim 1, wherein said protein is characterised by the following:
(i) it is present on the membrane of villous syncytiotrophoblast of human first trimester and term placentae but is not detected on villous cytotrophoblast cells of human placentae;
(ii) on SDS-polyacrylamide gel electrophoresis under both reducing and non-reducing conditions it migrates principally as a species of molecular weight of 63-67kDa; and
(iii) it is a glycoprotein which is estimated to contain 3-6 O-linked oligosaccharide chains and 5-10 complex N-linked oligosaccharide chains.
3. A vaccine according to claim 2, wherein said protein has an amino acid sequence substantially as shown in Table 1.
4. A vaccine according to any one of claims 1 to 3, further comprising an adjuvant.
5. A vaccine according to claim 4, wherein said adjuvant comprises an emulsion of muramyl dipeptide and squalene-Avlacel A.
6. A vaccine according to any one of claims 1 to 5, further comprising a second immunogen in order to enhance the immunogenicity of said active immunogen.
7. A vaccine according to claim 6 wherein said second immunogen is diphtheria toxin.
8. A vaccine according to any one of claims 1 to 5, wherein said active immunogen is in the form of a fusion protein with a heterologous protein or peptide moiety.
9. A vaccine according to claim 8, wherein said heterologous moiety is β-galactosidase or glutathione-S-transferase.
10. A method for the prevention or inhibition of pregnancy in a female animal, including a woman, which comprises administration to said female animal of an antibody-stimulating effective amount of a vaccine according to any one of claims 1 to 9.
11. Human trophoblast membrane expressed protein in substantially pure form, said protein being characterised by the following:
(i) it is present on the membrane of villous syncytiotrophoblast of human first trimester and term placentae but is not detected on villous cytotrophoblast cells of human placentae;
(ii) on SDS-polyacrylamide gel electrophoresis under both reducing and non-reducing conditions it migrates principally as a species of molecular weight of 63-67kDa; and (iii) it is a glycoprotein which is estimated to contain 3-6 O-linked oligosaccharide chains and 5-10 complex N-linked oligosaccharide chains.
12. A protein according to claim 11, having an amino acid sequence substantially as shown in Table 1.
13. An immunologically-active fragment of human trophoblast membrane expressed protein according to claim 11 or claim 12.
14. Antibodies to human trophoblast membrane expressed protein according to claim 11 or claim 12, or an immunologically-active fragment thereof.
15. A monoclonal antibody according to claim 14.
16. A method for the preparation of human trophoblast membrane expressed protein according to claim 11 or claim 12 in substantially pure form, which comprises contacting human placental tissue with antibody according to claim 14 or claim 15, and recovering the desired protein antigen from the antigen/antibody complex.
17. A method according to claim 16, wherein said antibody is adsorbed or covalently bound to a solid support to assist in separating the antigen/antibody complex.
18. A method for the preparation of human trophoblast membrane expressed protein according to claim 11 or claim 12, or an immunologically-active fragment thereof, which comprises expression of a nucleotide sequence coding for said protein or fragment thereof in a host cell having said nucleotide sequence inserted therein, and recovering said protein or fragment.
19. A method according to claim 18, wherein said protein or fragment thereof is expressed in the form of a fusion protein with a heterologous protein or peptide moiety.
20. Use of human trophoblast membrane expressed protein or of an immunologically-active fragment thereof, in the manufacture of a vaccine for the prevention or inhibition of pregnancy in a female animal, including a woman.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPK865591 | 1991-09-30 | ||
AUPK8655 | 1991-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1993006857A1 true WO1993006857A1 (en) | 1993-04-15 |
Family
ID=3775725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/AU1992/000519 WO1993006857A1 (en) | 1991-09-30 | 1992-09-30 | Preparation and use of human trophoblast membrane expressed protein in an anti-fertility vaccine |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO1993006857A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19964044A1 (en) * | 1999-12-30 | 2001-08-02 | Frank Hans Georg | Identifying peptides which mimic groups of mammalian trophoblasts |
WO2003004533A1 (en) * | 2001-07-04 | 2003-01-16 | Aplagen Gmbh | Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4646689A (en) * | 1988-12-06 | 1990-06-26 | Flinders Technologies Pty Ltd | Isolation of fetal cells from maternal blood to enable prenatal diagnosis |
-
1992
- 1992-09-30 WO PCT/AU1992/000519 patent/WO1993006857A1/en active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4646689A (en) * | 1988-12-06 | 1990-06-26 | Flinders Technologies Pty Ltd | Isolation of fetal cells from maternal blood to enable prenatal diagnosis |
Non-Patent Citations (1)
Title |
---|
PAGE FAULK, W.; HSI, B.L., "Immunobiology of Human Trophoblast Membrane Antigens", from BIOLOGY OF TROPHOBLAST, Edited by LOKE, Y.W., WHYTE, A., published by ELSEVIER SCIENCE PUBLISHERS in AMSTERDAM, NETHERLANDS, in 1983, pages 535-70. * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19964044A1 (en) * | 1999-12-30 | 2001-08-02 | Frank Hans Georg | Identifying peptides which mimic groups of mammalian trophoblasts |
DE19964044C2 (en) * | 1999-12-30 | 2001-11-22 | Frank Hans Georg | Method of identifying substances that mimic mammalian epitopes |
WO2003004533A1 (en) * | 2001-07-04 | 2003-01-16 | Aplagen Gmbh | Immunological binding molecules inhibiting the syncytial fusion of trophoblast cells |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0461177B1 (en) | Human intra-acrosomal sperm antigen for use in a contraceptive vaccine | |
Hearn | Immunization against pregnancy | |
US5626846A (en) | Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides | |
GB2268179A (en) | Antibodies to purified HCG receptors | |
AU2017431494A1 (en) | Long-acting recombinant porcine fsh fusion protein, and preparation method and application thereof | |
US4966888A (en) | hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine | |
CA1057742A (en) | Antigenic modification of polypeptides | |
JPH05500654A (en) | Contraceptive vaccine based on cloned zona pellucida gene | |
Schwoebel et al. | Molecular analysis of the antigenicity and immunogenicity of recombinant zona pellucida antigens in a primate model | |
WO1993006857A1 (en) | Preparation and use of human trophoblast membrane expressed protein in an anti-fertility vaccine | |
US6469139B1 (en) | Modified human chorionic gonadotropin (β-hCG) proteins and their medical use | |
Naz et al. | Monoclonal antibody against human sperm-specific YLP 12 peptide sequence involved in oocyte binding | |
Yurewicz et al. | Generation and characterization of site-directed antisera against an amino-terminal segment of a 55 kDa sperm adhesive glycoprotein from zona pellucida of pig oocytes | |
Gupta et al. | Characteristics and bioefficacy of monoclonal antigonadotropin releasing hormone antibody | |
Lee et al. | Studies of a sperm/placenta cross-reacting antigen, STX-10 | |
US6723556B1 (en) | Nucleic acid encoding a fragment of bovine luteinizing hormone/chorionic gonadotropin receptor | |
Kamada et al. | Antisperm antibody: a monkey wrench in conception/magic bullet of contraception? | |
CA1085383A (en) | Antigenic modification of polypeptides | |
Pal et al. | Biological actions of monoclonal antibodies to bovine lutropin receptor | |
CN100381467C (en) | UreG protein, and its preparing method and sue | |
AU630862B2 (en) | Method of preparation and use for zona pellucida antigens and antibodies for sterilization and contraception | |
Koyama et al. | Antibody responses to a synthetic pZP4 peptide recognized by a fertilization-blocking monoclonal antibody | |
Naz | Cloning and Sequencing of Sperm Antigens Involved in Oocyte Interaction: Clinical applications in infertility and immunocontraception | |
US20050032171A1 (en) | hCG-hLH receptor and hCG-hLH receptor-hCG complex as antigens, antibodies thereto and contraceptive vaccine | |
Saxty et al. | Sperm surface antigens and the prospects for contraceptive vaccine development |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA FI JP KR NO US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: US Ref document number: 1994 211244 Date of ref document: 19940630 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: CA |
|
122 | Ep: pct application non-entry in european phase |